Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 13/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796402 | 1.00 | PRKDC (1.00) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL29467770 | 1.00 | PRKDC (1.00) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL6396107 | 0.81 | PRKDC (0.68) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL6396110 | 0.81 | PRKDC (0.68) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL3802701 | 0.76 | AURKA (0.68) | PRKDCAURKAAURKBFGFR1KDR | |
| SCHEMBL3802699 | 0.76 | AURKA (0.68) | PRKDCAURKAAURKBFGFR1KDR | |
| SCHEMBL3796467 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB | |
| SCHEMBL3802455 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB | |
| SCHEMBL3796473 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB | |
| SCHEMBL3802448 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | claimed |
| US-7732483-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-7732483-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| WO-2009008991-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080242664-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242664-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-7402607-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-7402607-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | PRKAB1, PRKAG1, PRKAB2 | PRKDC 81/4885AURKA 1657/4885AURKB 793/4885 |
| US-20080242664-A1 | DNA-PK INHIBITORS | XRCC6, XRCC5, POLK | PRKDC 284/4885AURKA 329/4885AURKB 212/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | PRKDC 101/4885AURKA 78/4885AURKB 125/4885 |
| US-20070238731-A1 | Dna-Pk Inhibitors | XRCC6, XRCC5, POLK | PRKDC 317/4885AURKA 378/4885AURKB 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.